Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Mainz, DEU
Freiligrathstrasse 12
Mainz, 55131, DEU

People

Funding

TOTAL $57.9M
FUNDING TOTAL $57.9M
Series E, 11/2013
MIG Fond
ATS Beteiligungsverwaltung
FCPB
€45M

Tags

Ganymed Pharmaceuticals

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Recent Milestones

Videos

Screenshots

Ganymed Pharmaceuticals screenshot
Above: Homepage
Uploaded: 11/18/13

Sources

  1. Ganymed Pharmaceuticals Closes EUR 45 Million Financing Round (b3cnewswire.com) [edit]
Edit This Page
Last Edited 12/26/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy